Navigation Links
Aethlon Medical, Inc. Announces Annual Meeting Results

SAN DIEGO, Sept. 16 /PRNewswire/ -- Aethlon Medical, Inc. (OTC Bulletin Board: AEMD), reported that at its annual meeting of stockholders completed today in San Diego, California, the stockholders re-elected the incumbent four-person Board of Directors.

Shareholders also:

  • ratified the appointment of Squar, Milner, Peterson, Miranda & Williamson LLP as independent auditors for the fiscal year ending March 31, 2010;
  • approved an increase in authorized shares of its common stock from 100 million shares to 250 million shares.


Based on the preliminary report from the Inspector of Elections, approximately 82.4 percent of outstanding shares were represented at the meeting and each director received affirmative votes from 99.2 percent or more of the shares voted. Shareholders also ratified Squar, Milner, Peterson, Miranda & Williamson LLP as Aethlon's independent accountants, with affirmative votes from approximately 99.4 percent of the shares that were represented at the meeting. Shareholders ratified the measure to increase the limit on authorized shares, with affirmative votes from approximately 93.0 percent of the shares that were represented at the meeting.

Final vote totals will be included in the company's quarterly report for the fiscal quarter ending September 30, 2009 to be filed with the United States Securities and Exchange Commission.

Jim Joyce, Chairman and Chief Executive Officer of Aethlon Medical, Inc. said, "We truly appreciate the overwhelming support received from our shareholders."

About Aethlon Medical, Inc.

Aethlon Medical creates diagnostic and therapeutic device solutions for infectious disease and cancer. Our Hemopurifier(R) represents the first-in-class medical device to selectively adsorb viruses and immunosuppressive toxins from the bloodstream. The Hemopurifier(R) seeks to improve Hepatitis-C treatment outcomes and serves as a broad-spectrum treatment countermeasure against bioterror and pandemic threats. Additional information regarding Aethlon Medical can be accessed online at

Forward-looking Statements

This release contains forward-looking statements which reflect management's current views of future events and operations including but not limited to estimates of financial performance and cash flows, trends in subscriber preference and engagement and results of marketing strategies. These statements are based on current expectations and assumptions that are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include the risk of changing economic conditions, the impact of executive management transitions, failure of product demand or market acceptance of both existing and new products and services and the impact of competitive products and pricing. Please see Aethlon Medical, Inc.'s recent filings with the Securities and Exchange Commission for information about these and other risks that may affect the Company. All forward-looking statements included in this release are based on information available to us on the date hereof. These statements speak only as of the date hereof, and Aethlon Medical, Inc. does not undertake to publicly update or revise any of its forward-looking statements, even if experience or future changes show that the indicated results or events will not be realized.


    Jon Cunningham
    RedChip Companies Inc.
    (407) 644-4256
    (407) 491-4498 -cell

    Jim Joyce
    Chairman, CEO
    858.459.7800 x301

    Jim Frakes
    Senior VP Finance
    858.459.7800 x300

SOURCE Aethlon Medical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Aethlon Medical Announces Data Supported Strategy to Increase Hepatitis-C (HCV) Cure Rates
2. China Sky One Medical, Inc. Responds to Concerns Regarding Filed Financial Reports
3. China Sky One Medical, Inc. Announces Record Second Quarter 2009 Results
4. China Sky One Medical, Inc. Announces Conference Call to Discuss Second Quarter 2009 Results
5. Angiotechs Licensee, Cook Medical, Announces CE Mark Approval and European Launch of the Zilver(R) PTX(R) Stent
6. China Sky One Medical, Inc. Appoints New Independent Director
7. Powerful Image Registration and Recognition Software Unveiled for Medical, Satellite, and Defense Imaging Industries
8. China Sky One Medical, Inc. Obtains Production Approval for Two New Drugs
9. China Sky One Medical, Inc. Signs Agreement with Taiwan Golden Biotechnology Corp. on Development of New Anti-Cancer Drug
10. China Sky One Medical, Inc. Appoints Pricewaterhouse Coopers to Help Develop a SOX 404 Compliance Program
11. China Sky One Medical, Inc. Schedules Conference Call to Discuss First Quarter 2009 Results
Post Your Comments:
(Date:11/30/2015)... Florida , November 30, 2015 ... specializing in the development of innovative peptide and gene-based ... metastatic disease, today announced it will be presenting at ... on December 1, 2015 at 2.30 PM PT. Dr. ... and Strategic Advisor will be giving the presentation and ...
(Date:11/30/2015)... 2015  Aytu BioScience, Inc. (OTCQB: AYTU), a commercial-stage ... will present at two upcoming investor conferences. Aytu is ... virtual conference, to be held December 3, 2015, and ... held December 2 nd & 3 rd , ... streamed live via webcast. Josh Disbrow , ...
(Date:11/30/2015)... RATON, Florida and MAGDEBURG, Germany ... Congress of NeuroRehabilitation (ECNR) in Vienna, Austria ... 3rd European Congress of NeuroRehabilitation (ECNR) in ... 2015. --> NovaVision, a wholly owned subsidiary of ... the European version of its Internet-delivered NovaVision Therapy Suite at ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... integration with MarkLogic, the Enterprise NoSQL database platform provider, creating a seamless ... , Smartlogic’s Content Intelligence capabilities provide a robust set of semantic tools ...
Breaking Biology Technology:
(Date:11/19/2015)... -- Although some 350 companies are actively involved in molecular ... according to Kalorama Information. These include Roche Diagnostics, Hologic, Abbott ... of the 6.1 billion-dollar molecular testing market, according to ... Diagnostic s .    ... one company and only a handful of companies can ...
(Date:11/17/2015)... 17, 2015 Paris from ... --> Paris from 17 th until ... biometrics innovation leader, has invented the first combined scanner in ... same scanning surface. Until now two different scanners were required: ... can capture both on the same surface. This innovation ...
(Date:11/17/2015)... EASTON, Mass. , Nov. 17, 2015 ... a leader in the development and sale of broadly ... the worldwide life sciences industry, today announced it has ... of its $5 million Private Placement (the "Offering"), increasing ... to $4,025,000.  One or more additional closings are expected ...
Breaking Biology News(10 mins):